Marc Engelhardt Selected Research

Mycoses (Diseases, Fungus)

1/2023	Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.
1/2019	Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
11/2018	Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
7/2018	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
1/2017	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
7/2016	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
1/2016	Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Engelhardt Research Topics

Disease

7	Neoplasms (Cancer) 04/2024 - 11/2018
7	Mycoses (Diseases, Fungus) 01/2023 - 01/2016
5	Infections 10/2021 - 10/2017
4	Aspergillosis 01/2019 - 01/2017
3	Bacteremia 12/2023 - 01/2020
3	Pneumonia (Pneumonitis) 01/2021 - 02/2019
2	Healthcare-Associated Pneumonia 01/2021 - 07/2014
2	Mucormycosis 01/2017 - 07/2016
1	Carcinoma (Carcinomatosis) 04/2024
1	Nausea 10/2023
1	Body Weight (Weight, Body) 10/2023
1	Glioblastoma (Glioblastoma Multiforme) 01/2023
1	Lymphoma (Lymphomas) 01/2023
1	Ovarian Neoplasms (Ovarian Cancer) 01/2023
1	Stomatitis 11/2021
1	Hand-Foot Syndrome 11/2021
1	Cholangiocarcinoma 11/2021
1	Ventilator-Associated Pneumonia 01/2021
1	Endocarditis 01/2020
1	Bacterial Pneumonia 11/2019
1	Communicable Diseases (Infectious Diseases) 11/2019
1	Chronic Obstructive Pulmonary Disease (COPD) 02/2019
1	Invasive Candidiasis 01/2019
1	Candidiasis (Moniliasis) 01/2019
1	Candidemia 01/2019
1	Neutropenia 01/2018
1	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2017
1	Mucositis 01/2017
1	Cryptococcosis 01/2016
1	Bone Resorption 04/2008

Drug/Important Bio-Agent (IBA)

9	isavuconazoleIBA 01/2023 - 01/2016
7	ceftobiproleIBA 12/2023 - 02/2019
4	lisavanbulinIBA 01/2023 - 01/2020
3	Anti-Bacterial Agents (Antibiotics)IBA 10/2023 - 11/2017
3	ProdrugsIBA 01/2023 - 07/2016
3	Voriconazole (Vfend)FDA LinkGeneric 01/2019 - 10/2017
2	derazantinibIBA 04/2024 - 11/2021
2	Aztreonam FDA LinkGeneric 10/2023 - 10/2021
2	Daptomycin FDA Link 10/2023 - 01/2020
2	BAL27862IBA 01/2023 - 10/2020
1	atezolizumabIBA 04/2024
1	Phosphotransferases (Kinase)IBA 04/2024
1	Cephalosporins (Cephalosporin Antibiotics)IBA 10/2023
1	PlatinumIBA 01/2023
1	Pemetrexed (MTA)FDA Link 01/2023
1	Investigational DrugsIBA 11/2021
1	Retinaldehyde (Retinal)IBA 11/2021
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 11/2021
1	Vancomycin FDA LinkGeneric 10/2021
1	Lysine (L-Lysine)FDA Link 10/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2019
1	Caspofungin (Cancidas)FDA Link 01/2019
1	Sodium Glutamate (Accent)IBA 11/2018
1	LactamsIBA 11/2017
1	BAL 30072IBA 11/2017
1	posaconazole FDA Link 10/2017
1	Immunosuppressive Agents (Immunosuppressants)IBA 10/2017
1	TriazolesIBA 10/2017
1	Itraconazole (Sporanox)FDA LinkGeneric 10/2017
1	Antifungal AgentsIBA 10/2017
1	Cytochrome P-450 CYP3AIBA 10/2017
1	Amphotericin B (Amphotericin)FDA LinkGeneric 07/2016
1	Ceftazidime (Fortum)FDA LinkGeneric 07/2014
1	Linezolid (Zyvox)FDA Link 07/2014
1	ceftobiprole medocarilIBA 07/2014
1	Biomarkers (Surrogate Marker)IBA 04/2008

Therapy/Procedure

4	Therapeutics 02/2019 - 01/2017
1	Mechanical Ventilators (Ventilator) 11/2019
1	Critical Care (Surgical Intensive Care) 11/2019
1	Hematopoietic Stem Cell Transplantation 10/2017